Every material Form 8-K Xylem has filed with the SEC since October 15, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Xylem reported third-quarter 2026 revenue of $2.2 billion, down 3% on a reported basis and flat organically, while reported earnings per share rose 34% to $1.25. The company lowered its full-year 2026 adjusted EPS guidance to $5.40-$5.45 from $5.55-$5.70 and cut its revenue forecast to a 1% decline from a prior 2% gain, and it said it intends to divest Applied Water International and Specialty Flow Control and reorganize into three segments in 2027.
Q3 2026 revenue was $2.2 billion, down 3% on a reported basis; adjusted EPS was $1.44, up 5%, and reported EPS was $1.25, up 34%
Full-year 2026 revenue is now expected at about $8.95 billion, down 1% reported, versus prior guidance of up 2%
Full-year 2026 adjusted EPS guidance was lowered to $5.40-$5.45 from $5.55-$5.70
Executive Hayati Yarkadas will cease to be an executive officer on January 1, 2027 and will lead the planned divestitures, with a $1.2 million success incentive tied to their closing
Xylem entered into a new five-year, $1.5 billion senior unsecured revolving credit facility on September 8, 2026, and terminated its $1.0 billion facility from March 2023 at the same time. The company says the new facility will fund working capital and general corporate purposes, and no borrowings were outstanding on the filing date.
New facility: up to $1.5 billion, five years, available in U.S. dollars and Euros, with accordion increases of up to $500 million to a $2.0 billion maximum
Terminated 2023 facility: $1.0 billion, dated March 1, 2023, with citibank, N.A. as administrative agent
No borrowings outstanding under the new agreement as of September 8, 2026; loans carry a leverage-based covenant on total debt to EBITDA
Xylem said CFO William Grogan will resign effective August 31, 2026 to pursue another opportunity, and Andrea van der Berg, currently SVP Finance for the Water Infrastructure segment, will become CFO on September 1, 2026. Xylem also reaffirmed its third-quarter and full-year 2026 guidance issued July 28, 2026, which matters to shareholders because it signals no change to the outlook alongside the finance leadership change.
Grogan remains employed through September 13, 2026 to support the transition.
Van der Berg's annual base salary is $675,000, with an AIP target of 80% of base salary.
Van der Berg receives a one-time 2026 LTIP award with a grant date value of $787,500, and a new LTIP target award of $1,750,000.
Xylem reaffirmed its third-quarter and full-year 2026 guidance issued July 28, 2026.
Xylem expanded its Board of Directors from 9 to 10 members and appointed D. Christian Koch to fill the new seat, effective immediately on August 13, 2026. The Board determined Koch is independent, and he also joined the Leadership Development and Compensation Committee and the Nominating and Governance Committee. Koch currently serves as Chairman, President and Chief Executive Officer of Carlisle Companies Incorporated, and the filing states he will receive standard non-employee director compensation, prorated for the current term.
Board size increased from 9 to 10 directors; Koch appointed to fill the vacancy effective August 13, 2026
Koch joins the Leadership Development and Compensation Committee and the Nominating and Governance Committee
Board determined Koch is independent under NYSE listing standards and SEC rules
Koch is Chairman, President and CEO of Carlisle Companies Incorporated; compensation follows the 2026 Proxy Statement filed March 20, 2026, prorated for the current term
Xylem reported second-quarter 2026 revenue of $2.3 billion, up 2% on a reported basis, and net income attributable to Xylem of $263 million, or $1.11 per share, up 19%. The company raised its full-year adjusted EPS guidance to $5.55 to $5.70 from $5.35 to $5.60, but lowered its full-year revenue growth forecast to about 2% from 2% to 3%.
Q2 2026 adjusted EPS was $1.46, up 16%; orders were $3.1 billion, up 42% on a reported basis
Full-year 2026 adjusted EPS guidance raised to $5.55 to $5.70 from $5.35 to $5.60
Full-year 2026 revenue forecast of about $9.2 billion, up about 2% reported, versus 2% to 3% previously guided
Q2 adjusted EBITDA margin was 23.3%, up 150 basis points year over year
Xylem completed a $1 billion public offering of two series of senior unsecured notes on May 29, 2026. The company plans to use the 2033 notes' proceeds to repay its $500 million 3.250% notes due November 1, 2026, and the 2036 proceeds to fund eligible blue projects, which adds debt that shareholders will need to see serviced.
$500 million of 5.200% Senior Notes due June 1, 2033
$500 million of 5.450% Senior Blue Notes due June 1, 2036
Proceeds from the 2033 notes intended to repay $500 million of 3.250% notes maturing November 1, 2026
Interest payable semiannually on June 1 and December 1, starting December 1, 2026
Xylem reported first-quarter 2026 revenue of $2.1 billion, up 3% on a reported basis but flat organically, and diluted EPS of $0.79, up 14%. Adjusted EPS was $1.12, up 9%. The company raised its full-year 2026 reported revenue forecast to $9.2 to $9.3 billion, while keeping its adjusted EPS guidance of $5.35 to $5.60 unchanged.
Q1 2026 revenue of $2.1 billion, up 3% reported and flat organically; orders of $2.2 billion, up 3% reported
Diluted EPS $0.79 vs. $0.69 a year earlier; adjusted EPS $1.12 vs. $1.03
2026 revenue guidance raised to $9.2 to $9.3 billion, up 2% to 3% reported, from 1% to 3% previously
Adjusted EPS guidance of $5.35 to $5.60 kept in line with prior range; repurchases of common stock totaled $563 million in Q1
Xylem reported fourth-quarter and full-year 2025 results on February 10, 2026. Fourth-quarter revenue rose 6% to $2.4 billion and adjusted EPS rose 20% to $1.42, while GAAP EPS rose 2% to $1.37 because of higher restructuring and realignment costs. The company initiated 2026 guidance of $9.1 to $9.2 billion in revenue and $5.35 to $5.60 in adjusted EPS, and declared a first-quarter dividend of $0.43 per share, up 8%.
Q4 2025 revenue of $2.4 billion, up 6% reported and 4% organic; GAAP EPS $1.37, up 2%; adjusted EPS $1.42, up 20%
Full-year 2025 revenue of $9.0 billion, up 6%; GAAP diluted EPS $3.92, up 7%; adjusted EPS $5.08, up 19%
2026 guidance: revenue of $9.1 to $9.2 billion and adjusted EPS of $5.35 to $5.60
Quarterly dividend of $0.43 per share, up 8%, payable March 24, 2026 to holders of record as of February 24, 2026
Xylem reported third-quarter 2025 revenue of $2.3 billion, up 8% on a reported basis and 7% organically, and reported diluted EPS of $0.93, up 4%. Adjusted EPS rose 23% to $1.37, and the company raised its full-year 2025 revenue and adjusted EPS guidance, which matters to shareholders because it reflects higher expected earnings for the year.
Q3 2025 revenue was $2.3 billion, up 8% reported and 7% organic; net income attributable to Xylem was $227 million
Q3 2025 EPS was $0.93 reported, up 4%, and $1.37 adjusted, up 23% from $1.11
Full-year 2025 revenue guidance is about $9.0 billion, up 5% to 6% reported versus 4% to 5% previously
Full-year 2025 adjusted EPS guidance is $5.03 to $5.08, up from the previous $4.70 to $4.85
Xylem reported second-quarter 2025 revenue of $2.3 billion, up 6% on both reported and organic bases, and earnings per share of $0.93, up 16%. The company raised its full-year 2025 revenue and adjusted earnings per share guidance, which matters to shareholders because both headline measures improved and the outlook was lifted.
Q2 2025 revenue was $2.3 billion, up 6% on reported and organic bases.
Q2 net income attributable to Xylem was $226 million, or $0.93 per share, up 16%; adjusted EPS was $1.26, also up 16%.
Full-year 2025 adjusted EPS guidance was raised to $4.70 to $4.85 from $4.50 to $4.70.
Full-year 2025 revenue is now forecast at about $8.9 to $9.0 billion, up about 4 to 5% on a reported basis, versus 1 to 2% previously.
Xylem reported first-quarter 2025 revenue of $2.1 billion, up 2% on a reported basis, and diluted EPS of $0.69, up 10%; adjusted EPS was $1.03, up 14%. The company raised its full-year 2025 revenue forecast to $8.7 to $8.8 billion, up 1 to 2% on a reported basis from 0 to 2% previously, and reaffirmed full-year adjusted EPS guidance of $4.50 to $4.70.
Q1 2025 revenue was $2.069 billion versus $2.033 billion a year earlier; net income attributable to Xylem was $169 million, or $0.69 per share, versus $153 million, or $0.63.
Adjusted EPS of $1.03 compares with $0.90 in Q1 2024; adjusted EBITDA margin was 20.4%, up 120 basis points.
Full-year 2025 revenue guidance was raised to approximately $8.7 to $8.8 billion, while adjusted EPS guidance of $4.50 to $4.70 was reaffirmed.
Q1 operating cash flow was $33 million, down from $89 million a year earlier.
Xylem reported fourth-quarter 2024 revenue of $2.3 billion, up 7%, and full-year revenue of $8.6 billion, up 16% on a reported basis and 6% organically. Q4 reported EPS was $1.34 (up 22%) and adjusted EPS was $1.18 (up 19%); reported results include a non-recurring gain on remeasurement of its previously held Idrica equity interest. The company guided 2025 revenue of about $8.6 to $8.7 billion and adjusted EPS of $4.50 to $4.70, and declared a $0.40 quarterly dividend, up 11%.
Q4 2024 revenue $2.3 billion, up 7% on a reported and organic basis; orders $2.2 billion, up 7%
Q4 adjusted EPS $1.18, up 19%; reported EPS $1.34, up 22%, including a non-recurring Idrica remeasurement gain
2025 guidance: revenue of about $8.6 to $8.7 billion, adjusted EBITDA margin of 21.3% to 21.8%, adjusted EPS of $4.50 to $4.70
First-quarter dividend of $0.40 per share, up 11%, payable March 19, 2025 to holders of record as of February 18, 2025
Xylem said its fourth-quarter and full-year 2024 results will be largely in line with or above its prior guidance, and that management committed on January 28, 2025 to a restructuring plan with workforce reductions across all businesses and functions. The company expects pre-tax charges of $95 million to $115 million, mostly in 2025, which will weigh on reported profit while the cuts aim to streamline the organization.
Q4 and full-year 2024 results expected to be largely in line with or above guidance given October 31, 2024
Restructuring committed January 28, 2025, with workforce reductions across all businesses and functions
Pre-tax charges of approximately $95 million to $115 million, primarily in 2025, including about $19 million in Q4 2024
Most workforce reductions expected in fiscal 2025, with some in 2026, subject to local laws
Xylem director Jeanne Beliveau-Dunn told the board on January 10, 2025 that she will not seek re-election at the 2025 annual meeting of shareholders. She will remain on the board until that meeting, and the company says the decision was not due to any disagreement over operations, policies or practices. The board will shrink to nine members when she departs.
Jeanne Beliveau-Dunn notified the board on January 10, 2025 of her decision not to stand for re-election.
She will continue to serve as a director until the 2025 annual meeting of shareholders.
The filing states her decision was not due to any disagreement with the company or the board.
Board size will be reduced to nine members effective with her departure.
Xylem reported third-quarter 2024 revenue of $2.1 billion, up 1% on both reported and organic bases, with diluted EPS of $0.89, up 41%, and adjusted EPS of $1.11, up 12%. The company narrowed its full-year adjusted EPS guidance to $4.22 to $4.24 from $4.18 to $4.28, and expects full-year revenue of $8.5 billion.
Q3 revenue was $2,104 million, up from $2,076 million a year earlier; net income was $217 million versus $152 million.
Q3 diluted EPS was $0.89 versus $0.63; adjusted EPS was $1.11 versus $0.99.
Full-year 2024 adjusted EPS guidance narrowed to $4.22 to $4.24, from $4.18 to $4.28.
Q3 adjusted EBITDA margin was 21.2%, up 140 basis points year over year; orders rose 8%.
Xylem Inc. said Meredith Emmerich will become Senior Vice President and President, Applied Water, effective October 21, 2024, succeeding Franz Cerwinka. Cerwinka will leave his current role on October 21 and remain as an advisor until his termination date of on or about March 31, 2025, under a transition agreement. The filing discloses a leadership change in one of the company's four reportable segments but no financial results.
Meredith Emmerich, formerly Vice President at Carrier Global Corporation, becomes Senior Vice President and President, Applied Water, effective October 21, 2024.
Franz Cerwinka ceases to hold his role effective October 21, 2024, and stays on as an advisor until on or about March 31, 2025.
Cerwinka's transition agreement keeps his base salary at an annual rate of $570,630 and allows continued vesting of equity awards through the termination date.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Xylem filing is on SEC EDGAR ↗. 8-K briefs of other companies →